Startups
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM
Overview
Location
United States, Nevada, Incline Village
Employees
11-50
Phone
+1 604-669-7207
Total raised
$8M
Founded date
1981
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 6, 2023 | InMed to Participate in Upcoming Investor Events | Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - InMed Pharmaceuticals Inc. INM ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and c... |
| Nov 10, 2021 | InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update - Form 8-K | InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update Vancouver, BC - November 10, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in ... |
| Nov 10, 2021 | InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update | VANCOUVER, British Columbia., Nov. 10, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced fina... |
| Nov 3, 2021 | InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid - Form 8-K | InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid ● Patent covers novel effects for neurodegenerative diseases ● Expands InMed's patent portfolio with incremental rare cannabi... |
| Nov 3, 2021 | InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid | Patent covers novel effects for neurodegenerative diseases Expands InMed’s patent portfolio with incremental rare cannabinoid VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company... |
| Sep 24, 2021 | InMed Pharmaceuticals : Annual Report (SEC Filing - 10-K) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐TRANSITION REPORT... |
| Nov 16, 2020 | InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering | |
| Nov 12, 2020 | InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM" | |
| Mar 20, 2019 | Amyris teams up with LAVVAN to bring fermentation-derived CBD to market in 2020: 'There's a significant cost advantage' | The news follows a string of announcements from firms also developing platforms to biosynthesize cannabinoids via fermentation including Demetrix, Librede; InMed Pharmaceuticals; Hyasynth, which is working with Organingram; Gingk... |
Show more
Reviews 0
FAQ about InMed Pharmaceuticals
When was InMed Pharmaceuticals founded?
InMed Pharmaceuticals was founded in 1981.
How much funding has InMed Pharmaceuticals raised?
InMed Pharmaceuticals has raised $8M in total across 1 funding round.
What has the press written about InMed Pharmaceuticals?
Parsers VC has collected 11 articles mentioning InMed Pharmaceuticals, among them “InMed to Participate in Upcoming Investor Events” (Mar 6, 2023) and “InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update - Form 8-K” (Nov 10, 2021).
Is InMed Pharmaceuticals still active?
Yes, InMed Pharmaceuticals is active; its latest activity on Parsers VC dates from Jul 13, 2026.